SCHEMBL4564643

SCHEMBL4564643

CCCCCNc1ccc(C(C)=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.51
SCN5A Q14524 2/20 0.51
CYP1A2 P05177 1/20 0.51
MAOA P21397 1/20 0.51
CNR1 P21554 1/20 0.51
DRD4 P21917 1/20 0.51
ACHE P22303 1/20 0.51
HRH2 P25021 1/20 0.51
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51
MAPK1 P28482 1/20 0.51
NTSR1 P30989 1/20 0.51
HRH1 P35367 1/20 0.51
DRD3 P35462 1/20 0.51
SCN1A P35498 1/20 0.51
HTR2B P41595 1/20 0.51
SCN7A Q01118 1/20 0.51
SLC6A3 Q01959 1/20 0.51
KCNH2 Q12809 1/20 0.51
SCN9A Q15858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11281162 0.98 PLK1 (0.52) LMNASCN5ACYP1A2MAOACNR1
SCHEMBL19149288 0.98 PLK1 (0.52) LMNASCN5ACYP1A2MAOACNR1
SCHEMBL11299855 0.98 PLK1 (0.52) LMNASCN5ACYP1A2MAOACNR1
SCHEMBL11278232 0.98 PLK1 (0.52) LMNASCN5ACYP1A2MAOACNR1
SCHEMBL11273058 0.98 PLK1 (0.52) LMNASCN5ACYP1A2MAOACNR1
SCHEMBL11278081 0.98 PLK1 (0.52) LMNASCN5ACYP1A2MAOACNR1
SCHEMBL11281214 0.98 PLK1 (0.52) LMNASCN5ACYP1A2MAOACNR1
SCHEMBL10997394 0.95 LMNA (0.56) LMNASCN5ACYP1A2MAOACNR1
SCHEMBL14535153 0.87 NPC1 (0.49) LMNASCN5ACYP1A2MAOACNR1
SCHEMBL2825925 0.86 HCAR3 (0.60) LMNASCN5ACYP1A2MAOACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230139366-A1 BRARTEMICIN ANALOGUES VICTORIA LINK LIMITED (NZ) 2023-05-04 US disclosed
US-7572938-B2 Precursors for ketones and aldehydes GIVAUDAN SA (CH) 2009-08-11 US disclosed
US-20040171516-A1 Precursors for ketones and aldehydes GIVAUDAN SA (CH) 2004-09-02 US disclosed
EP-1390337-A1 PRECURSORS FOR KETONES AND ALDEHYDES Givaudan SA (CH) 2004-02-25 EP disclosed
WO-2002096850-A1 PRECURSORS FOR KETONES AND ALDEHYDES GIVAUDAN SA (CH) 2002-12-05 WO disclosed
EP-1262473-A1 Precursors for fragrant ketones and fragrant aldehydes Givaudan SA (CH) 2002-12-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139366-A1 BRARTEMICIN ANALOGUES RXFP1, RXFP2, RXFP4 LMNA 3705/4885SCN5A 3662/4885CYP1A2 4571/4885
US-20040171516-A1 Precursors for ketones and aldehydes PDK3, PDK4, AKR1C4 LMNA 1452/4885SCN5A 1091/4885CYP1A2 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.